C
Complete Omics
Innovative molecular diagnostics and OMICs technologies for cancer proteomics and genomics
About Complete Omics
Complete Omics Inc. is a pioneering company in the field of molecular diagnostics, focusing on the detection and quantification of biomarkers for personalized cancer treatment. Founded by Dr. Qing Wang and a team of expert scientists, the company leverages advanced technologies like Mass Spectrometry and Next Generation Sequencing (NGS) to identify mutant proteins specific to cancer. This allows for highly personalized and precise cancer therapies.
Read full description
The company operates in the healthcare and biotechnology market, serving a diverse range of clients including hospitals, research institutions, and pharmaceutical companies. Complete Omics specializes in multi-omics platforms, which means they analyze various biological data types such as genomics, proteomics, and metabolomics to provide comprehensive insights into an individual's health.
Complete Omics' business model revolves around offering specialized diagnostic services and products. They have developed a series of optimized sample processing and purification procedures that significantly enhance the sensitivity and accuracy of their tests. Their flagship service, the Complete Clinical Proteomics pipeline, is designed to be the most sensitive and specific tool for clinical proteomics, aiding in the development of personalized cancer therapeutics.
Revenue is generated through service contracts with healthcare providers and research institutions, as well as through the sale of diagnostic kits and software solutions. The company also collaborates with pharmaceutical firms to develop targeted cancer therapies, providing another revenue stream.
In summary, Complete Omics is at the forefront of personalized medicine, using cutting-edge technology to improve cancer diagnosis and treatment. Their commitment to innovation and precision makes them a valuable player in the healthcare industry.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Arbutus, United States
- Employees
- 14
- Open positions
- None listed
- Dealroom signal
- 83.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Nov 2023 | $10M | $40M | Qiming Venture Partners | ↗ |
| SPINOUTOther financing | Jan 2019 | — | — | Johns Hopkins University | — |
Growth signals
Latest recorded traffic for Complete Omics is 1.7K monthly website visits, up 107.3% over the last three months. Complete Omics's team grew 27.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Other known investors1 additional known investor
Johns Hopkins University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Complete Omics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Complete Omics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.